Eaton, C., Wells, J., Holen, I., Croucher, P., & Hamdy, F. (2004). Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
शिकागो शैली (17वां संस्करण) प्रशस्ति पत्रEaton, C., J. Wells, I. Holen, P. Croucher, और F. Hamdy. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.
एमएलए (9वां संस्करण) प्रशस्ति पत्रEaton, C., et al. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.